# Dune Medical Devices

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dune-medical-devices

- Industry: Medical Devices & Equipment
- Headquarters: Alpharetta, US
- Website: www.dunemedical.com
- Total disclosed funding: $44M
- Latest round: Series D (Jul 6, 2017)
- Investors on record: 5

## About

Dune Medical Devices is focused on improving surgical outcomes through innovative medical technologies, particularly in the field of intraoperative diagnostics and tissue analysis.Founded in 2002, Dune Medical Devices, headquartered in Alpharetta, US, develops solutions aimed at enhancing surgical precision. In April 2020, it was acquired by Dilon Technologies, Inc. The company has completed 6 deals with the latest funding round being Series D, where it raised USD 12.30 mn from investors including ATON Partners, Evidity Health Capital, and The Kraft Group, bringing the total amount raised to USD 12.30 mn.Dune Medical Devices offers advanced technology solutions designed to improve surgical processes, with a focus on intraoperative diagnostics. Their primary offerings include innovative systems that assist surgeons in real-time tissue analysis, helping to ensure optimal surgical outcomes. The company serves a diverse clientele, including hospitals and surgical centers, and has a presence in North America, Europe, and parts of Asia, addressing the needs of the healthcare industry.Dune Medical Devices operates on a subscription model, allowing medical institutions to access its diagnostic technologies regularly. Clients choose service tiers tailored to their operational requirements, which may encompass various features such as enhanced diagnostic capabilities and customer support. The flagship product significantly contributes to revenue, aided by partnerships with key players in the healthcare sector, thus establishing a stable revenue stream from both new and loyal clients.Following its acquisition in April 2020, Dune Medical Devices aims to expand its product suite by developing new diagnostic technologies set for release in the next year. The company plans to enter additional markets across Europe and Asia by late 2023, leveraging recent funding of USD 12.30 mn to support these initiatives and enhance their market position.

## Funding rounds

- Series D, Jul 6, 2017, $12M — Kraft Group, Evidity Health Capital, ATON Partners
- Series C, Jun 26, 2014, $14M — Kraft Group, Evidity Health Capital
- Series B, Jun 28, 2006, $13M — Apax Partners
- Series A, Mar 29, 2004, $5M — Apax Partners, Zeev Mozes

## Investors

- Apax Partners (https://capitalatlas.ai/funds/apax-partners) — Series A, Series B
- Zeev Mozes — Series A
- Kraft Group — Series C, Series D
- Evidity Health Capital (https://capitalatlas.ai/funds/evidity-health-capital) — Series C, Series D
- ATON Partners (https://capitalatlas.ai/funds/aton-partners) — Series D